semaxinib and fosbretabulin

semaxinib has been researched along with fosbretabulin* in 2 studies

Other Studies

2 other study(ies) available for semaxinib and fosbretabulin

Article	Year
Structure-activity-relationship studies of conformationally restricted analogs of combretastatin A-4 derived from SU5416. Bioorganic & medicinal chemistry, 2006, Oct-01, Volume: 14, Issue:19 A series of combretastatin A-4 analogs derived from the ATP competitive, VEGF receptor tyrosine kinase inhibitor, SU5416 were synthesized. The cytotoxic effects of the analogs were evaluated against PC-3 and MDA-MB-231 cancer cell lines, as well as their abilities to inhibit tubulin polymerization. Results are compared to those of compound 1, our lead compound previously reported. Topics: Antineoplastic Agents, Phytogenic; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromatography, High Pressure Liquid; DNA, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Indoles; Isomerism; Magnetic Resonance Spectroscopy; Molecular Conformation; Podophyllotoxin; Pyrroles; Stilbenes; Structure-Activity Relationship; Tubulin	2006
Conformationally restricted analogs of Combretastatin A-4 derived from SU5416. Bioorganic & medicinal chemistry letters, 2005, Dec-15, Volume: 15, Issue:24 A series of compounds originally derived from the vascular endothelial growth factor receptor tyrosine kinase inhibitor, SU5416, was synthesized and evaluated. The most potent compound in this series, compound 7, structurally resembles the potent anti-microtubule agent Combretastatin A-4, inhibited tubulin polymerization, and showed potent growth inhibitory activities on both prostate and breast cancer lines with IC(50) values in low to subnanomolar range. Topics: Animals; Antineoplastic Agents; Brain; Cell Division; Indoles; Models, Molecular; Molecular Conformation; Pyrroles; Stilbenes; Swine; Tubulin	2005

Article

Year

Structure-activity-relationship studies of conformationally restricted analogs of combretastatin A-4 derived from SU5416.

Bioorganic & medicinal chemistry, 2006, Oct-01, Volume: 14, Issue:19

A series of combretastatin A-4 analogs derived from the ATP competitive, VEGF receptor tyrosine kinase inhibitor, SU5416 were synthesized. The cytotoxic effects of the analogs were evaluated against PC-3 and MDA-MB-231 cancer cell lines, as well as their abilities to inhibit tubulin polymerization. Results are compared to those of compound 1, our lead compound previously reported.

Topics: Antineoplastic Agents, Phytogenic; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromatography, High Pressure Liquid; DNA, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Indoles; Isomerism; Magnetic Resonance Spectroscopy; Molecular Conformation; Podophyllotoxin; Pyrroles; Stilbenes; Structure-Activity Relationship; Tubulin

2006

Conformationally restricted analogs of Combretastatin A-4 derived from SU5416.

Bioorganic & medicinal chemistry letters, 2005, Dec-15, Volume: 15, Issue:24

A series of compounds originally derived from the vascular endothelial growth factor receptor tyrosine kinase inhibitor, SU5416, was synthesized and evaluated. The most potent compound in this series, compound 7, structurally resembles the potent anti-microtubule agent Combretastatin A-4, inhibited tubulin polymerization, and showed potent growth inhibitory activities on both prostate and breast cancer lines with IC(50) values in low to subnanomolar range.

Topics: Animals; Antineoplastic Agents; Brain; Cell Division; Indoles; Models, Molecular; Molecular Conformation; Pyrroles; Stilbenes; Swine; Tubulin

2005